The first direct activator of BAX, a pro-apoptotic member of the BCL-2 family, has been recently identified. Herein, a structure-based lead optimization turned out into a small series of analogues, where 8 is the most potent compound published so far. 8 was used as pharmacological tool to ascertain, for the first time, the anticancer potential of BAX direct activators and the obtained results would suggest that BAX direct activators are potential future anticancer drugs rather than venoms.
Structure-based lead optimization and biological evaluation of BAX direct activators as novel potential anticancer agents
STORNAIUOLO, MARIANO
Primo
;GRASSIA, GIANLUCA;LA PIETRA, VALERIA;GIUSTINIANO, MARIATERESA;CASSESE, HILDE;DI MARO, SALVATORE;BRANCACCIO, DIEGO;IALENTI, ARMANDO;NOVELLINO, ETTORE;MARINELLI, LUCIANA
2015
Abstract
The first direct activator of BAX, a pro-apoptotic member of the BCL-2 family, has been recently identified. Herein, a structure-based lead optimization turned out into a small series of analogues, where 8 is the most potent compound published so far. 8 was used as pharmacological tool to ascertain, for the first time, the anticancer potential of BAX direct activators and the obtained results would suggest that BAX direct activators are potential future anticancer drugs rather than venoms.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
jm501123r.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Accesso privato/ristretto
Dimensione
6.72 MB
Formato
Adobe PDF
|
6.72 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
